Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

Poliomyelitis Clinical Trial

Official title:

An Open-label Primary Vaccination Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Three-dose Primary Vaccination Course at 2, 3 and 4 Months of Age in Healthy Infants in China.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00937404
• Other study ID #: 112581
• Status: Completed
• Phase: Phase 1
• Start date: August 4, 2009
• Est. completion date: November 13, 2009

Study information

• Verified date: May 2018
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will evaluate the safety and reactogenicity of Poliorix given as primary vaccination course to Chinese children at 2, 3 and 4 months of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: November 13, 2009
• Est. primary completion date: November 13, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 60 Days to 90 Days

Eligibility

Inclusion Criteria:

• A male or female infant between, and including, 60 and 90 days of age at the time of the first vaccination.

• Born after a gestation period of 36 to 42 weeks inclusive.

• Subjects who the investigator believes that their parents/ guardians can and will comply with the requirements of the protocol should be enrolled in the study.

• Written informed consent obtained from the parent or guardian of the subject.

• Healthy subjects as established by medical history and clinical examination before entering into the study.

Exclusion Criteria:

• Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.

• Chronic administration of immunosuppressants or other immune-modifying drugs since birth.

• Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.

• Administration of a vaccine not foreseen by the study protocol within 30 days prior to vaccination, or planned administration during the study period, with exception of DTP, Hib and/or hepatitis B vaccine(s).

• Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.

• Evidence of previous or intercurrent poliomyelitis disease or vaccination.

• History of seizures or progressive neurological disease.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.

• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s).

• Major congenital defects or serious chronic illness. The following condition is temporary or self-limiting and a subject may be vaccinated once the condition has resolved and no other exclusion criteria are met:

• Current febrile illness or axillary temperature > 37.0 ºC or other moderate to severe illness within 24 hours of study vaccine administration.

Related Conditions & MeSH terms

• Poliomyelitis

Intervention

Biological:
• Poliorix
All subjects receive three doses of Poliorix vaccine, administered intramuscularly into the upper right side of the thigh.

Locations

Country	Name	City	State
China	GSK Investigational Site	Wuzhou	Guangxi

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects Reporting Solicited Local Symptoms	Solicited local symptoms assessed were pain, redness and swelling. Any = occurrence of the symptom irrespective of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 30 millimetres (mm) of injection site.	During the 4-day follow-up period after each dose of study vaccine.
Primary	Number of Subjects Reporting Solicited General Symptoms	Assessed solicited general symptoms were drowsiness, irritability, loss of appetite and fever [defined as axillary temperature equal to or above (=) 37.1 degrees Celsius (°C)]. Any = occurrence of symptom regardless of intensity grade of relationship to vaccination. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 irritability = crying that could not be comforted/prevented normal activity. Grade 3 loss of appetite = subject did not eat at all. Grade 3 fever = fever above (>) 39.0°C. Related = symptom assessed by the investigator as related to vaccination.	During the 4-day follow-up period after each dose of study vaccine.
Primary	Number of Subjects Reporting Unsolicited Adverse Events (AEs)	Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.	During the 31-days follow-up period after each dose of the study vaccine.
Primary	Number of Subjects Reporting Serious Adverse Events (SAEs)	SAEs assessed included any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity or was a congenital anomaly/birth defect in the offspring of a study subject.	During the entire study period (from Dose 1 up to one month following last vaccine dose).

External Links

•   Results for study 112581 can be found on the GSK Clinical Study Register